EU Regulators Recommended Two New Cancer Treatments
The European Committee for Medicinal Products for Human Use backed approvals for Klygefa and Enhertu.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to prioritize patient health during the drug approval process?
European regulators have recommended Klygefa for adults with generalized myasthenia gravis and Enhertu for patients with HER2-positive breast cancer. These endorsements follow clinical trial data confirming significant efficacy in managing both conditions.
Why it matters
These recommendations represent a major step toward making targeted therapies available for patients facing high risks of disease recurrence. The approvals are based on clinical evidence, including studies showing significant risk reductions for treated populations.
The Phase III DESTINY-Breast05 trial reported a 53% risk reduction for cancer recurrence or death when using Enhertu compared to T-DM1. After three years, 92% of Enhertu patients remained disease-free, compared to 84% for those on T-DM1.
The players
European Committee for Medicinal Products for Human Use
This body is responsible for providing opinions on medicinal products for human use within the European Union.
Astrazeneca
This multinational pharmaceutical and biotechnology company focuses on prescription medicines across major disease areas.
The details
Klygefa is a dual-binding nanobody C5 inhibitor designed to assist adults with AChR-positive gMG, while Enhertu is intended for patients with persistent invasive disease following neoadjuvant therapy. The Klygefa recommendation stems from the 26-week PREVAIL study, which demonstrated patient symptom improvements against a placebo.
Timeline
The PREVAIL study for Klygefa spanned 26 weeks.
Patient invasive disease-free status was monitored over a period of three years.
Astrazeneca share prices were reported at 0915 BST.
The Big Picture
The regulatory recommendation for Enhertu is a direct extension of the findings established by the DESTINY-Breast05 clinical trial.
These regulatory steps indicate that patients may soon gain access to advanced treatments like Klygefa and Enhertu, which have demonstrated better outcomes than current standard options. Patients should consult with their oncologists to understand how these evolving treatment standards might apply to their specific medical profile.
The takeaway
These clinical findings suggest that targeted pharmaceutical interventions continue to yield higher disease-free survival rates in oncology. Patients and families can discuss the clinical potential of these therapies with their healthcare providers as regulatory processes move forward globally.
Further reading
Learn more about new therapeutic developments in Cancer.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health during the drug approval process?
